Effect of Systemic Matrix Metalloproteinase Inhibition on Periodontal Wound Repair: A Proof of Concept Trial

R. Gapski,* J.L. Barr,* D.P. Sarment,* M.G. Layher,* S.S. Socransky,† and W.V. Giannobile*‡

Background: The adjunctive use of matrix metalloproteinase (MMP) inhibitors with scaling and root planing (SRP) promotes new attachment in patients with periodontal disease. This pilot study was designed to examine aspects of the biological response brought about by the MMP inhibitor low dose doxycycline (LDD) combined with access flap surgery (AFS) on the modulation of periodontal wound repair in patients with severe chronic periodontitis.

Methods: Twenty-four subjects were enrolled into a 12-month, randomized, placebo-controlled, double-masked trial to evaluate clinical, biochemical, and microbial measures of disease in response to 6 months therapy of either placebo capsules + AFS or LDD (20 mg b.i.d.) + AFS. Clinical measures including probing depth (PD), clinical attachment levels (CAL), and bleeding on probing (BOP) as well as gingival crevicular fluid bone marker assessment (ICTP) and microbial DNA analysis (levels and proportions of 40 bacterial species) were performed at baseline and 3, 6, 9, and 12 months.

Results: Patients treated with LDD + AFS showed more potent reductions in PD in surgically treated sites of >6 mm (P <0.05, 12 months). Furthermore, LDD + AFS resulted in greater reductions in ICTP levels compared to placebo + AFS. Rebounds in ICTP levels were noted when the drug was withdrawn. No statistical differences between the groups in mean counts were found for any pathogen tested.

Conclusions: This pilot study suggests that LDD in combination with AFS may improve the response of surgical therapy in reducing probing depth in severe chronic periodontal disease. LDD administration also tends to reduce local periodontal bone resorption during drug administration. The use of LDD did not appear to contribute to any significant shifts in the microbiota beyond that of surgery alone. J Periodontol 2004;75:441-452.

KEY WORDS
Bone resorption/prevention and control; doxycycline/therapeutic use; periodontal attachment; periodontal diseases/therapy; surgical flaps.

Although periodontitis is initiated by subgingival microbiota, it is generally accepted that mediators of connective tissue breakdown are generated to a large extent by the host’s response to the pathogenic infection.1 In a susceptible host, microbial virulence factors trigger the release of host-derived enzymes such as proteases (e.g., matrix metalloproteinases [MMPs]) which can lead to periodontal tissue destruction.2-4 Collagenases, a subclass of the MMP family, are a group of enzymes capable of disrupting the triple helix of type I collagen in physiological conditions, the primary structural component of the periodontium. Elevated levels of collagenases and other host-derived proteinases (e.g., cathepsins, elastase, trypsin) have been detected in inflamed gingiva, gingival crevicular fluid (GCF), and saliva of humans with periodontal disease.5-7

Studies have shown that tetracyclines (including the semi-synthetic analogues minocycline and doxycycline) are capable of inhibiting mammalian collagenase activity.8,9 Tetracycline’s inhibitory effect on collagenases appears to occur through the drug’s ability to bind to zinc ions as well as calcium ions in the catalytic domain of the MMP molecule.10,11 In fact, tetracycline also inhibits another class of Ca++ dependent metalloproteinases termed gelatinases (or type IV collagenases)12 and prevents the degradation of a serum protein called α1-proteinase inhibitor (or α1-antitrypsin).13 Furthermore, administration of low doses of doxycycline (LDD; a tetracycline analog) given 20 mg b.i.d.
rather than the 50 or 100 mg capsules, typically administered as commercially available antibiotics, effectively inhibit collagenase activity in the gingival tissues as well as in GCF without exerting direct effects on the subgingival microorganisms.

Investigations have demonstrated the efficacy of LDD therapy on promoting probing depth (PD) reduction and clinical attachment level (CAL) gains when combined with scaling and root planing (SRP) therapy in chronic periodontitis patients. Caton and co-workers, in a multi-center clinical trial, found that a 9-month regimen of LDD + SRP provided statistically significant improvements in CAL, PD, and bleeding on probing (BOP) over a 9-month period compared to placebo + SRP in periodontitis patients.

Many of the crucial cellular responses of early postsurgical wound healing, such as inflammatory infiltration, angiogenesis, and reepithelialization, are made possible through the action of MMPs. In addition, the amount and organization of normal wound extracellular matrix are determined by a dynamic balance among overall matrix synthesis, deposition, and degradation. Expression of MMPs such as collagenases and gelatinases are elevated in acute wounds and still greater levels are found in chronic wounds, indicating that uncontrolled proteolysis is a characteristic of retarded healing. Porcine skin wound models have demonstrated that collagenase has early peak expression at 1 to 7 days post-wounding, followed by slow reduction postoperatively with time, with the sharpest decline occurring after completion of epithelialization. The importance of collagen turnover kinetics mediated by MMP expression during wound healing can be demonstrated in diabetes. It has been shown in both preclinical and human studies that uncontrolled hyperglycemia may impair wound healing, and this impairment seems to be directly associated with overexpression of MMPs in the wound site. Furthermore, the utilization of CMT-1 (a chemically modified tetracycline that lacks antimicrobial properties but retains the utilization of CMT-1) in diabetic rats by increasing both steady-state levels of type I procollagen mRNA and collagen synthesis through mechanism(s) that are independent of the antibacterial properties of tetracyclines. In another preclinical study, STZ-induced diabetic rats exhibited cessation of periosteal and cancellous bone formation. Interestingly, treatment of diabetic animals with 20 mg/day of minocycline (a semisynthetic tetracycline) showed increased bone formation rates comparable to control animals. Moreover, growth plate thickness, reduced 43% in diabetic rats, were preserved in the diabetic animals treated with minocycline. Therefore, inhibition of elevated levels of specific MMPs during the early phases of tissue repair may contribute to improved treatment outcomes by promoting a favorable wound healing in both connective tissue and bone.

The emphasis of this pilot, placebo-controlled, double-masked clinical investigation was to examine clinical and laboratory measures of periodontal status resulting from a 6-month regimen of LDD on postsurgical periodontal healing in patients with severe chronic periodontitis. Clinical, microbiological, and biochemical parameters were monitored over a 12-month period to determine the biological response of LDD on surgical periodontal therapy.

**MATERIALS AND METHODS**

**Study Population**

A written informed consent was provided for individuals willing to participate in this trial who met the inclusion and exclusion criteria outlined in a protocol approved by the University of Michigan Institutional Review Board. Twenty-four subjects (aged 30 to 75 years) diagnosed with severe chronic periodontitis were enrolled into a pilot, double-masked, randomized, placebo-controlled, prospective, parallel arm trial. Pertinent inclusion criteria included patients with at least three teeth in the same sextant demonstrating both PD and CAL ≥5 mm to ≤12 mm and BOP. The patients also had to have at least 10 teeth in the functional dentition. Exclusion criteria included chronic treatment (i.e., 2 weeks or more) with any medication known to affect periodontal status (i.e., antibiotics or non-steroidal, anti-inflammatory drugs); antibiotic treatment within 90 days of baseline; clinically significant or unstable organic diseases; compromised healing potential such as connective tissue disorders or bone metabolic diseases; conditions necessitating antibiotic prophylaxis; females who were pregnant (as determined by positive urine pregnancy test at the prescreening visit) or lactating, or who were of child-bearing potential and not utilizing birth control or abstinence; documented allergies to tetracyclines; heavy cigarette smokers (≥2 packs/day); active infectious diseases; immunocompromised; or taking steroid medications. All dental care related to this trial was provided at no cost to eligible participants.

**Study Design**

Patients eligible to participate in the study received full-mouth SRP within 90 days of baseline (surgery). Fourteen days prior to surgery, subjects were again examined (screening visit) and inclusion/exclusion criteria reviewed. In this visit, two prescreened patients did not meet the inclusion criteria due to healing from SRP. Subjects who still qualified for the study and required access flap surgery (AFS) in a minimum of one sextant were randomized to receive either doxycycline hyclate 20 mg b.i.d. or Periostat, CollaGenex Pharmaceuticals, Inc., Newtown, PA.

§ Periostat, CollaGenex Pharmaceuticals, Inc., Newtown, PA.
line appointment. Six sites were measured around each tooth in the mouth (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual, and mesio-lingual) for PD, CAL, and BOP. At the same visit, microbiological parameters and gingival crevicular fluid (GCF) samples were collected on teeth assigned to receive surgery. Examiners (JLB and MGL) were trained and calibrated to minimize intra-rater (i.e., intraexaminer) variability. In addition, in order to minimize the impact of inter-rater variability on the sensitivity of this study, the same examiner assessed the same patients for the duration of the trial.

Surgical procedures were then performed at baseline (BL) within 14 days of the screening visit by one surgeon (RG). Patients returned for follow-up examinations at months 1, 2, 3, 6, 9, and 12 following baseline. Full-mouth manual probing measurements, GCF, ICTP levels, and microbiological samples were assessed at BL and months 3, 6, 9, and 12. Patients received periodontal maintenance therapy at 3, 6, 9, and 12 months following randomization and periodontal surgery. The study design is shown in Table 1.

**Surgical Procedure**

Briefly, following local anesthesia, treatment sextants received AFS, which consisted of submarginal primary incisions (Fig. 1A) and full-thickness mucoperiosteal flap reflection. The tooth root surfaces were debrided, scaled and root planed using hand and sonic instrumentation. Osseous recontouring (osteoplasty) when indicated was performed for flap adaptation (Fig. 1B). The tissues were repositioned with polyglactin 910 or silk suture materials (Fig. 1C). The surgical sites were then covered with a periodontal dressing. After surgery, patients

---

**Table 1.**

**Clinical Trial Longitudinal Measures**

<table>
<thead>
<tr>
<th>Event</th>
<th>Pre-Screening</th>
<th>Screening</th>
<th>Baseline</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRP</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full-mouth measurements</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbial sampling</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urine pregnancy test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Surgery</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-telopeptide level</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Maintenance therapy</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dispense medication</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug accountability</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Figure 1.**

Access flap surgical procedure in a patient administered 20 mg b.i.d. LDD for a period of 6 months, followed by an additional 6 months. **A) Scalloping incisions made to remove the collar of gingival tissue.** **B) After flap reflection, the surgical site was debrided followed by SRP and osteoplasty where necessary.** **C) Flaps were repositioned utilizing interrupted sutures 4-0 polyglactin 910. Periodontal dressing was placed and 0.12% chlorhexidine rinses utilized for 14 days.** **D) LDD-treated sextant 1 year post-LDD therapy + surgery. Note clinical appearance of normal gingival architecture and healing.**
received pain control medication (an acetaminophen-containing analgesic) when needed and chemical plaque control (0.12% chlorhexidine rinse) for 14 days.

Dispensing of Study Medication/Assessment of Compliance
At the screening visit, qualifying patients were assigned a code and were then randomized by a computer software program to the drug or placebo group. At the baseline visit, each patient was issued a 3-month supply of coded study medication including one container for morning and another for afternoon/evening intake. Three months following surgery, subjects returned residual capsules and received an additional 3-month supply. The residual capsules were counted and retained at 3 and 6 months after baseline. Patient compliance (as a percentage) with the dosing schedule was recorded.

Microbiological Monitoring
Subgingival plaque samples were collected from the mesio-buccal sites of each tooth scheduled for surgery using sterile curets. Samples were then placed in sterile, labeled tubes containing 150 µL TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.6) and vortexed. Microbial analyses were performed for the presence and levels of 40 subgingival pathogens (Table 2) utilizing whole genomic DNA probes and checkerboard DNA-DNA hybridization as previously described. Signals were recorded as 0: not detected; 1: <10⁵ cells; 2: ∼10⁵ cells; 3: 10⁵ to 10⁶ cells; 4: ∼10⁶ cells; and 5: >10⁶ cells.

Bone Marker (ICTP) Analysis
Gingival crevicular fluid was collected prior to clinical measurements. Gingival tissue surrounding the site to be sampled was dried with gauze, and supragingival plaque was removed. A sterile methylcellulose strip was gently placed into the mesio-buccal aspect of each tooth sulcus or pocket until slight resistance was felt and the GCF collected for 10 seconds. Following collection, the sample was kept on ice for transport to the laboratory and stored at −80°C. The frozen samples were then thawed at room temperature and proteins were eluted through five centrifugations at 3,000 RPM for 5 minutes with 20 µL phosphate buffered saline (PBS, pH 7.4) containing 15 nM aprotinin, 1 mM PMSF, and 0.1% human serum albumin as previously described. GCF ICTP levels were quantified using radioimmunoassay.

Gingival Biopsies (Protease Determination)
Six patients (3 from test group, 3 from placebo group) scheduled to receive two sextants of surgery were evaluated for changes in gingival proteinase activity, utilizing gelatin zymography. Excised tissues from each treatment sextant were immediately placed on ice and subsequently frozen (−80°C). Two months later, tissue samples were harvested from another sextant, during a subsequent surgery. To prepare tissue extracts, samples were thawed on ice, homogenized in PBS, and centrifuged (10,000 × g for 10 minutes at 4°C). Protein concentration in the extracts was determined using a protein assay kit using bovine serum albumin (BSA) as a standard. The supernatants were diluted with an equal volume of glycerol and stored at −80°C. Protease activity was assessed by 12% gelatin zymography as previously described.

Statistical Analyses
Data available for each patient were subjected to an intent-to-treat analysis and included full-mouth clinical measurements for three different parameters (PD, CAL, PER).
and BOP) examined at six sites per tooth. Sample size determination for this pilot study was determined from Golub et al. using 80% power for differences expected in a primary biological outcome measure, the bone resorption marker, ICTP. The level and prevalence of 40 species and ICTP levels (pg/site) was measured from the surgically-treated quadrant excluding third molars. Clinical, microbial, and ICTP data were averaged within a patient and then compared between groups. In other analyses, data were stratified according to baseline PD of 1 to 4, 5 to 6, and ≥7 mm and averaged in a patient and then across the study population for clinical parameters and ICTP levels. Differences between drug and placebo groups were performed using the Mann-Whitney test. Differences with a P value less than 0.05 were considered significant. Microbiologic data were analyzed separately for sites receiving AFS + LDD and AFS + placebo. Mean levels (counts × 10⁵) for each of 40 species were computed for each patient in each treatment category at each visit. Significant differences over time were determined separately for each treatment category using the Quade test and the differences between groups were determined by the Mann-Whitney test. All analyses were performed using the patient as the unit of analysis.

RESULTS
Calibration
The results for calibration of the examiners revealed the intraclass correlation coefficients for PD were >0.90 and for CAL measurements were >0.85. Intraexaminer reliability was determined utilizing the percent agreement within 1 mm between 2 passes and a weighted kappa statistic. The percent agreement within 1 mm was ≥95.5% and ≥90% for PD and CAL measurements, respectively. The weighted kappa statistic was ≥0.92 and ≥0.88 for PD and CAL measurements, respectively.

Demographics
A total of 24 patients entered into the study; 12 were randomized to the LDD + AFS group and 12 to the placebo + AFS group. Ten out of 12 patients in the drug group and 11 out of 12 in the placebo group completed the study for an overall drop-out rate of 12.5%. One patient in the LDD group moved away while the other began administration of a calcium channel blocker that conflicted with the inclusion criteria. The patient in the placebo group reported lethargy after capsule intake and requested exit from the study. At baseline, there were no statistically significant differences (NS) between groups regarding age and gender (Table 3). There were two screening failures at baseline due to changes in PD and BOP. Treatment Outcomes: Responses in Clinical Parameters and ICTP

Table 3.
Baseline Mean (± SD) Clinical Characteristics and ICTP

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo (n = 12)</th>
<th>Drug (n = 12)</th>
<th>P (Mann-Whitney)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Mean (SD))</td>
<td>53.3 (±9.8)</td>
<td>45.9 (±8.3)</td>
<td>NS*</td>
</tr>
<tr>
<td>Range</td>
<td>38-71</td>
<td>32-60</td>
<td></td>
</tr>
<tr>
<td>% males</td>
<td>67%</td>
<td>67%</td>
<td>NS</td>
</tr>
<tr>
<td>Tobacco use (n [%])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>3 (25%)</td>
<td>5 (41.7%)</td>
<td></td>
</tr>
<tr>
<td>Past</td>
<td>6 (50%)</td>
<td>4 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>3 (25%)</td>
<td>3 (25%)</td>
<td></td>
</tr>
<tr>
<td>BOP (%)</td>
<td>51.3 (±19.3)</td>
<td>56.6 (±15.9)</td>
<td>NS</td>
</tr>
<tr>
<td>PD (mm)</td>
<td>3.0 (±0.5)</td>
<td>3.1 (±0.3)</td>
<td>NS</td>
</tr>
<tr>
<td>CAL (mm)</td>
<td>3.8 (±0.8)</td>
<td>4.1 (±0.8)</td>
<td>NS</td>
</tr>
<tr>
<td>ICTP (pg/site)</td>
<td>34.0 (±44.5)</td>
<td>52.0 (±54.2)</td>
<td></td>
</tr>
</tbody>
</table>

* Not significant.
As expected, both placebo and test groups demonstrated a statistically significant reduction in PD compared to baseline ($P < 0.001$); however, no differences between groups were found. Surgical therapy resulted in mean CAL gains in both groups ($P > 0.05$). The LDD group demonstrated a statistically significant reduction in percentage of BOP sites at 3 and 6 months compared to baseline ($25\%$ to $60\%$, $P < 0.05$) while in the placebo group, no statistical significance was found ($\sim 15\%$, $P > 0.05$). In addition, the LDD group demonstrated a decreased but not statistically significant expression of GCF ICTP levels compared to placebo during the drug administration period.

**Moderate sites (baseline PD 5 to 6 mm).** Mean per-patient averages in BOP, PD, CAL, and ICTP levels from baseline at surgical sites with a baseline PD of 5 to 6 mm are shown in Figure 4. Consistent with results from pooled PD strata, there were significant reductions in PD and gains in CAL compared to baseline for both drug and control groups, while no statistical difference between treatments was found although trends for a drug effect for PD reduction were noted. ICTP levels were reduced while patients were on LDD therapy, but a rebound in ICTP levels in the LDD + AFS group was demonstrated after patients discontinued the drug. There was a statistically significant reduction in the percent of BOP sites at 3 and 6 months compared to baseline in the LDD + AFS group ($P < 0.05$), while no such effect was seen in patients receiving placebo capsules ($P > 0.05$). Both LDD + AFS and placebo + AFS groups showed comparable levels in percentage of sites BOP after the patients discontinued drug therapy ($P > 0.05$).

**Deep sites (baseline PD $\geq 7$ mm).** Figure 5 shows the mean per-patient averages in BOP, PD, CAL, and ICTP levels for initially deep sites. Greater reductions in PD were noted in this stratum for both groups. Drug therapy resulted in more statistically significant reduction in PD in deep sites compared to controls ($P < 0.05$) and this difference was sustained for the duration of the study. However, no differences were found between groups with respect to CAL. In addition, patients receiving LDD + AFS showed greater reductions in ICTP levels compared to placebo + AFS during the first 6-month observation period, but no statistical differences were found ($P = 0.09$). This difference was also not significant when patients discontinued drug therapy. Again, LDD therapy resulted in a statistical reduction in the percent of BOP sites ($P < 0.05$) for 6 months while no such reductions were demonstrated in placebo controls ($P > 0.05$). However, these differences between groups were not significant by the end of the trial ($P > 0.05$).

**Microbial Outcomes**

Comparisons between LDD + AFS and placebo + AFS were performed utilizing mean microbial DNA counts of each microorganism averaged per patient and then per group. When interanalysis was performed, no statistically significant differences were found for any of the 40 microorganisms tested at any given time point (data not shown). There was an immediate reduction in red complex and orange complex species in both drug and placebo groups after AFS was performed (Fig. 6).

**Gelatin Zymography for Proteinase Expression**

Five patients (two LDD and three placebo) completed baseline and 2 months harvest of gingival tissues for
Gapski, Barr, Sarment, Layher, Socransky, Giannobile

Gelatin zymography analysis. After tissue preparation, zymograms were run in a standard manner, utilizing commercially available collagenases type IV as a positive control. Results generated from all patients demonstrated that a downregulation in gelatinase activity (mean 7.2%; range: 4.9% to 8.5%) in patients receiving adjunctive therapy, while an increase in activity was seen in the placebo group (mean 5.6%; range: −10.4% to 17.5%).

DISCUSSION

The purpose of the present investigation was to attempt to unravel biological changes that occur as a result of a combination of periodontal therapies with antibacterial effects (i.e., surgery) and host modulatory effects (i.e., LDD). The consideration of the bacterial-host interaction as a basic mechanism for periodontitis pathogenesis has driven the concept that successful long-term management of this disease may be dependent upon an effective control of bacterial load in combination with host modulatory therapies. To date, several bone-sparing agents or host modulatory drugs have been developed to control pathways responsible for periodontal tissue breakdown such as regulation of immune and inflammatory responses, excessive production of matrix metalloproteinases (MMPs), arachidonic acid metabolites, and regulation of bone metabolism.

This pilot investigation sought to evaluate the potential additive effect of LDD to modulate wound repair in conjunction with periodontal surgery. The goal was to explore the clinical, microbial, and biochemical impact of this drug on the modulation of wound healing post-surgically. Following mechanical therapy in the form of SRP, patients received access flap surgery and were randomized to LDD or placebo groups for 6 months of drug therapy, followed by a 6-month post-dosing evaluation. As expected, both therapies led to significant clinical improvements in terms of PD reduction and CAL gain (Figs. 3, 4, and 5). Patients in the placebo showed probing depth reductions and clinical attachment level gains similar to previously reported longitudinal studies, when the same therapy was compared.

Tetracycline analogues have been some of the most extensively investigated host modulatory agents and specifically, the low dose regimen of doxycycline hyclate (20 mg b.i.d.). Both preclinical and human clinical data have shown that tetracycline can suppress MMPs, which are considered to be primary enzymes responsible for the destruction of extracellular matrix macromolecules. Investigators have demonstrated the effects of adjunctive LDD in conjunction with supragingival scaling and dental prophylaxis, and SRP. Caton et al. indicated that a 9-month course of LDD with SRP resulted in statistically significant improvements in PD reduction and CAL gains when compared with placebo controls. The effects were maintained 12 months after initial therapy.

In this study, clinical efficacy was examined at sites with baseline PDs of 1 to 4 mm for shallow sulci/pockets (data not shown), 5 to 6 mm for moderate pockets (Fig. 4), and ≥7 mm for deep pockets (Fig. 5). This allowed analysis of the effects of LDD at sites fulfilling...
the criteria for periodontal surgery (i.e., PD ≥5 mm). In addition, the patients exhibited moderate to severe horizontal bone loss that is generally not indicated for traditional regenerative therapy. Therefore, patients included in this trial exhibited bone loss patterns with limited treatment options (non-surgical therapy or pocket reduction/elimination surgery). Although the present investigation was not designed as a definitive clinical trial, our results suggested a number of intriguing leads. When LDD was administered in combination with AFS, a greater probing depth reduction was found in deep sites of AFS + LDD subjects compared to controls (Fig. 5, P < 0.05). This result was maintained 6 months after discontinuation of the drug (Fig. 5, P < 0.05). However, no statistically significant differences between randomized groups were noted for CAL in any of the probing depth strata. There may be potential mechanisms that explain the PD reduction seen with LDD therapy: LDD therapy may promote more rapid wound maturation by inhibiting collagen disruption and indirectly encouraging collagen formation. Therefore, differences in timing, quality, and quantity of wound contraction in the periodontal tissues might have promoted additional PD reduction in the drug group.

The results of this study revealed a significant reduction in percentage of sites exhibiting BOP when patients were taking LDD as compared to the placebo group (Figs. 3, 4, and 5). These results are in agreement with a previous investigation,17 where a reduction in bleeding sites was seen in patients receiving adjunctive LDD compared to placebo. By contrast, Golub et al.9 reported only minimal and non-significant reductions in gingival inflammation and bleeding index51 with the use of LDD. In that study,9 the authors suggest that the improvement in periodontal conditions by LDD therapy was mainly by inhibiting collagen-destructive enzymes rather than affecting microbially-induced inflammation.9 However, it is important to note that the effects of LDD on BOP in our investigation also appeared to be independent of microbial shifts. Therefore, the effects of LDD on gingival inflammation (i.e., BOP) need to be further evaluated. In addition, it should be noted that both placebo and test groups experienced high BOP frequency at 12 months when deep probing depths were considered. The reason for that lies in the fact that the majority of patients were surgically treated only in the tested quadrant. In other words, remaining pockets after initial therapy on other quadrants might have served as reservoirs of putative bacteria that potentially infected the surgically-treated pockets. These findings have been confirmed by other investigations which reported that a natural recolonization of pathogenic microorganisms occurs after periodontal therapy.52-54 Therefore, this aspect could explain the high frequency of BOP in deep sites as well as recolonization of putative microorganisms found in this investigation (e.g., Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia).

LDD + AFS resulted in a decrease in the putative bone resorption marker ICTP soon after the surgical
therapy at 3 months while placebo controls demonstrated no change or increases in ICTP levels over the 12-month observation period. ICTP reflects the amount of organic matrix being disrupted in alveolar bone (specifically, type I collagen) following osteoclastic bone resorption. Human histological data have shown that osteoclastic activity peaks immediately after a surgical procedure is performed and is then followed by bone formation. Therefore, release of excessive osteoclastic collagenases (or MMP-13) may have increased the disruption of collagen type I in bone and consequently increased ICTP release in the placebo + AFS group. Golub et al. have demonstrated a direct effect of LDD therapy on the reduction of excessive MMP-13 followed by a concomitant decline in levels of collagen degradation fragments. In addition, it has been demonstrated that the increased circulating concentration of ICTP was most likely produced by action of MMPs. In the same study, cathepsin K-mediated bone resorption (an osteoclastic cysteine protease) destroyed ICTP antigenicity, further showing the specificity of MMPs on the initial disruption of bone collagen.

Hence, our findings have demonstrated that utilization of an MMP inhibitor may have a direct impact on postsurgical bone turnover. This result supports the notion that decreased collagenolytic activity (via LDD) can reduce bone resorption and act as a bone-sparing agent. Although these results are from only a small subset of patients from our investigation, these findings should encourage further exploration of the impact of host modulatory agents on bone maintenance.

With regard to the issue of low-dose antibiotics possibly resulting in direct microbial shifts, our study found no statistically significant differences between drug and control groups at any time point for any of the 40 tested species. These results are in agreement with previous human trials. It should also be noted that only surgical sites were evaluated for microbial analysis, therefore, effects of this drug on other sites are not available. When the data were analyzed according to bacterial complexes as proposed by Socransky et al., a reduction in periodontal pathogenic organisms was found in both groups, and this outcome was attributed to the effects of periodontal surgery. These findings are in concordance with recent reports that suggest that there is a beneficial effect of surgery on suppression of periodontal pathogens by eliminating reservoirs of virulent organisms. However, effects of continuous administration or cyclical dosing of LDD + surgery on microbial resistance or shifts were not evaluated in this study.

This investigation demonstrated no differences between groups regarding drug compliance. The overall compliance was approximately 80% with small tendencies for the patients to be more compliant in the morning and in the first 3 months of the drug administration period (NS; P >0.05). In our study, a wide range of compliance was found (18% to 100%) but it was also demonstrated that the majority of patients were reasonably compliant with the 6-month b.i.d. regimen (over 90% were >70% compliant).

**CONCLUSIONS**

Six-month administration of LDD suggests that there is an enhanced postsurgical wound healing compared
Systemic MMP Inhibition and Periodontal Wound Repair

Volume 75 • Number 3

Systemic MMP Inhibition and Periodontal Wound Repair

450

to placebo controls with regard to PD reduction. This positive effect was most marked in deep sites (≥7 mm), where the differences in PD reduction were maintained until the completion of the trial. Reductions in the bone resorption marker ICTP were also found in patients while on the drug, suggesting the potential of LDD to act as a bone-sparing agent. In addition, the percentage of BOP sites was affected by LDD therapy, but this effect was only noticeable during the period of the drug administration. Finally, no significant shifts on the periodontal microbiota beyond that attributable to the effects of the surgery could be seen with the utilization of LDD.

ACKNOWLEDGMENTS

The authors acknowledge the assistance of Drs. Qiming Jin, Amin ur Rahman, and Khalaf Al-Shammari during early stages of the investigation while at the University of Michigan, Ann Arbor, Michigan. The authors also appreciate the technical assistance of Denise Guerrero and Tina Yaskell, The Forsyth Institute, Boston, Massachusetts. We acknowledge Dr. Lorne Golub, State University of New York at Stony Brook, for critically reading the manuscript. This study was supported by NIH/NIDCR grants 5T35 DE07101, DE10977, and DE12861; ColaGenex Pharmaceuticals, Inc., Newtown, Pennsylvania; and the Delta Dental Fund of Michigan.

REFERENCES

12. Yu LP Jr., Smith GN Jr., Brandt KD, Myers SL, O’Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxy-


45. Ramfjord SP, Caffesse RG, Morrison EC, et al. Four


Correspondence: Dr. William V. Giannobile, Department of Periodontics/Prevention/Geriatrics, University of Michigan School of Dentistry, 1011 N. University Ave., Room 3397, Ann Arbor, MI 48109-1078. Fax: 734/763-5503; e-mail: wgiannob@umich.edu.

Accepted for publication July 22, 2003.